Compare GSK plc (GSK) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vanguard High Dividend Yield ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Vanguard High Dividend Yield ETF trades at $158.75 (market cap $100.80B). The key difference: GSK plc and Vanguard High Dividend Yield ETF are close in size by market cap, and GSK plc pays a 3.9% dividend while Vanguard High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Vanguard High Dividend Yield ETF for 139 Days on average.
| GSK | VYM | |
|---|---|---|
Market Cap | $91.88B | $100.80B |
Volume | 7,730,529 | 908,176 |
Sector | Health | — |
52-Week High | $61.18 | $167.03 |
52-Week Low | $43.24 | $137.47 |
Typical Hold Time | 93 Days | 139 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
VYM trades at $158.25, up 0.51% with a bearish technical signal. The ETF shows neutral momentum oscillators but bearish moving averages, with key support at $156 and resistance at $159. Recent news highlights VYM's consistent dividend yield of 2.42% but notes competitive pressure from alternatives like SCHD and IDV, which have outperformed recently. The fund's index methodology has faced criticism for holding stocks like Intel and Walgreens through dividend cuts.
Outlook remains cautious due to technical bearishness and competitive headwinds. While VYM offers broad diversification and low costs, investors face risks from its yield-focused strategy potentially including dividend-cut vulnerable stocks. The fund serves income investors but may underperform more dynamic dividend strategies in current market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
